STERIS prices $1.5B in notes to fund Xodus Medical buyout
What's the deal? STERISDealroom has a profile for this one. Try Dealroom → priced $1.5 billion in senior notes across two tranches on November 9, 2026, split into $750 million of 5.650% notes due 2033 and $750 million of 5.875% notes due 2036. J.P. Morgan Securities, Goldman SachsDealroom has a profile for this one. Try Dealroom →, Citigroup, BofA SecuritiesDealroom has a profile for this one. Try Dealroom →, PNC Capital Markets, and Wells Fargo SecuritiesDealroom has a profile for this one. Try Dealroom → are joint book-running managers. Settlement is scheduled for November 24, 2026.
Why now? The raise helps fund STERIS's pending $2.1 billion acquisition of Xodus MedicalDealroom has a profile for this one. Try Dealroom →, alongside a $500 million delayed-draw term loan and cash. The deal could also include up to $150 million in earnout payments.
What's the endgame? Xodus would expand STERIS's healthcare consumables and surgical-safety products. Management expects it to add to revenue, margins, and earnings.
By the numbers: The 2033 notes priced at 99.782% of par to yield 5.687%, a 92 basis-point spread over Treasuries; the 2036 notes priced at 99.852% to yield 5.894%, a 102 basis-point spread. The notes carry stable ratings of Baa1 from Moody's and BBB from both S&P and Fitch, and are set to list on the New York Stock Exchange.
What could go wrong? Management has flagged that the debt will bring added interest costs. The open question is whether Xodus's contribution justifies the heavier leverage. STERIS has also replaced its revolver with a larger $1.6 billion facility.
The signal: At $1.5 billion, this sits in the 93rd percentile of all post-IPO debt rounds raised by US health companies, underscoring the scale of acquisition financing in the sector. The move is an acquisition-driven debt raise, not a standalone capital top-up.
Read more: kalkinemedia.com
Image credit: NavyMedicine
